Evidence map›Paper›PMID 32522804›Full record

ArticleScience translational medicine2020

Molecular and functional extracellular vesicle analysis using nanopatterned microchips monitors tumor progression and metastasis.

Peng Zhang, Xiaoqing Wu, Gulhumay Gardashova, Yang Yang, Yaohua Zhang, Liang Xu, Yong Zeng

Open access · greenAbstract read
In one paragraph

Article in Science translational medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 67 papers.

0numbers the graph read from it
0cells of the map it votes in
67citing papers in PubMed
6.3field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

67 citing papers in PubMed, 135 citations in OpenAlex.

  1. Review
  2. Proteome of CD9Life (Basel, Switzerland) · 2026
    Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Review
  12. Review
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Review
  19. Review
  20. Article

7 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Peng ZhangDepartment of Chemistry, University of Kansas, Lawrence, KS 66045, USA.ORCID 0000-0002-0896-6411
Xiaoqing WuDepartment of Molecular Biosciences, University of Kansas, Lawrence, KS 66045, USA.ORCID 0000-0003-2076-4107
Gulhumay GardashovaDepartment of Molecular Biosciences, University of Kansas, Lawrence, KS 66045, USA.ORCID 0000-0002-2567-1893
Yang YangDepartment of Chemistry, University of Kansas, Lawrence, KS 66045, USA.ORCID 0000-0002-5524-0998
Yaohua ZhangBioengineering Graduate Program, University of Kansas, Lawrence, KS 66045, USA.
Liang XuDepartment of Molecular Biosciences, University of Kansas, Lawrence, KS 66045, USA. xul@ku.edu zengy@ufl.edu.ORCID 0000-0001-9196-4232
Yong ZengDepartment of Chemistry, University of Kansas, Lawrence, KS 66045, USA. xul@ku.edu zengy@ufl.edu.ORCID 0000-0003-0537-109X
University of Kansas · US

Funding

Transgenic & Gene-Targeting Shared ResourceP30CA168524 · NCI · UNIVERSITY OF KANSAS MEDICAL CENTER · PI NICOLE L NOLLEN · 2012 to 2026
$40.1M
Understanding the mechanobiology of stem cells in a microengineered 3D cardiac tissue environment with cardiomyopathyP20GM103638 · NIGMS · UNIVERSITY OF KANSAS LAWRENCE · PI HOLMSTROM, ERIK D · 2012 to 2021
$22.1M
Extracellular Vesicle Proteomic Fingerprinting of Ovarian Cancer for Early Detection with a Nanoengineered MicrosystemR01CA260132 · NCI · UNIVERSITY OF KANSAS MEDICAL CENTER · PI GODWIN, ANDREW K., ZENG, YONG · 2021 to 2025
$3.4M
Nano-Engineered Lab-on-a-Chip for Assessing HuR-Regulated Exosomes for Cancer Monitoring and Targeted TherapyR01CA243445 · NCI · UNIVERSITY OF KANSAS LAWRENCE · PI DIXON, DAN ALAN, XU, LIANG · 2019 to 2023
$3.0M
Molecular cancer therapy targeting HuR-ARE interactionR01CA191785 · NCI · UNIVERSITY OF KANSAS LAWRENCE · PI AUBE, JEFFREY, XU, LIANG · 2015 to 2019
$2.1M
Integrated exosomes profiling for minimally invasive diagnosis and monitoring of cancerR33CA214333 · NCI · UNIVERSITY OF KANSAS LAWRENCE · PI GODWIN, ANDREW K., SAMUEL, GLENSON · 2017 to 2019
$1.2M
Integrated Digital Microfluidic Platforms for Next-Generation GlycomicsR21CA207816 · NCI · UNIVERSITY OF KANSAS LAWRENCE · PI ZENG, YONG · 2016 to 2017
$585k
Microfluidic Integrative Circulating miRNA Profiling for Cancer DiagnosisR21EB024101 · NIBIB · UNIVERSITY OF KANSAS LAWRENCE · PI DOYLE, PATRICK S, ZENG, YONG · 2017 to 2018
$411k
NCI NIH HHS P30 CA168524NCI NIH HHS R01 CA191785NCI NIH HHS R01 CA243445NCI NIH HHS R01 CA260132NCI NIH HHS R21 CA207816NCI NIH HHS R33 CA214333NIBIB NIH HHS R21 EB024101NIGMS NIH HHS P20 GM103638
6 · The paper itself

Abstract

Longitudinal cancer monitoring is crucial to clinical implementation of precision medicine. There is growing evidence indicating important functions of extracellular vesicles (EVs) in tumor progression and metastasis, including matrix remodeling via transporting matrix metalloproteases (MMPs). However, the clinical relevance of EVs remains largely undetermined, partially owing to challenges in EV analysis. Distinct from existing technologies mostly focused on characterizing molecular constituents of EVs, here we report a nanoengineered lab-on-a-chip system that enables integrative functional and molecular phenotyping of tumor-associated EVs. A generalized, high-resolution colloidal inkjet printing method was developed to allow robust and scalable manufacturing of three-dimensional (3D) nanopatterned devices. With this nanochip platform, we demonstrated integrative analysis of the expression and proteolytic activity of MMP14 on EVs to detect in vitro cell invasiveness and monitor in vivo tumor metastasis, using cancer cell lines and mouse models. Analysis of clinical plasma specimen showed that our technology could be used for cancer detection including accurate classification of age-matched controls and patients with ductal carcinoma in situ, invasive ductal carcinoma, or locally metastatic breast cancer in a training cohort (

Indexed as

Breast NeoplasmsExtracellular VesiclesAnimalsFemaleHumansLab-On-A-Chip DevicesLiquid BiopsyMicePrecision Medicine

Identifiers

PMID32522804
PMCPMC8024111
OpenAlexW3033727239

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.